Biosimilar Market Industry Trends 2027: Competitive Analysis and Segmentation

According to the recent report by IMARC Group, titled “Biosimilar Market: Global Industry Trends, Size, Share, Growth, Opportunity and Forecast 2022-2027”, the Biosimilars market reached a value of US$ 13.0 Billion in 2021. Catalyzed by these factors, the market is expected to reach US$ 60.8 Billion by 2027, exhibiting at a CAGR of 26.1% during 2022-2027.

Request for a PDF Sample of this Report:

Biosimilars are biotherapeutic products that are particularly identical to a reference biologic drug. They are produced using living organisms and cells that have complex molecular structures. To be labeled as a biosimilar, a biological drug must be proved similar in terms of efficacy, safety, and quality. Biosimilars are comparatively more expensive than generic drugs as their production process is complex and requires considerable investments in research and development (R&D) activities.

 Biosimilar Market Trends:

The surging prevalence of chronic diseases, such as cancer and autoimmune diseases, especially among the geriatric population, represents one of the key factors significantly contributing to the market growth. Additionally, the growing instances of patent expiration and loss of protection in several biologic drugs are creating a positive outlook for the market. The manufacturers have to resort to approval from the regulatory authorities once their patent expires to start the production of biosimilars. Moreover, biosimilars do not require extensive marketing, as the efficacy and safety profile of their branded counterparts has already been established, which, in turn, is working in favor of the market growth. Besides this, the high costs related to innovator biologics, especially monoclonal antibodies (mAbs), have compelled governments to undertake initiatives encouraging the usage of biosimilars over branded biologics due to their cost-effectiveness, which is accelerating the market growth.

Ask Analyst for Customization and Explore full report with TOC & List of Figures:

Biosimilar Market 2022-2027 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the Biosimilars market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

  • Novartis
  • Pfizer
  • Teva
  • Celltrion
  • Merck & Co
  • Samsung Bioepis
  • Eli Lilly
  • Biocon
  • Reddy’s Laboratories
  • Amgen
  • Boehringer Ingelheim

Key Market Segmentation:

Molecule insights: 

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa

Indication Insights:

  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility

Manufacturing Insights:

  • In-house Manufacturing
  • Contract Manufacturing

Regional Insights:

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India
  • South Korea
  • Others

We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.

Key Highlights of the Report:                                                           

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Market Trends
  • Market Drivers and Success Factors
  • Impact of COVID-19
  • Value Chain Analysis
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Table Of Content:

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Biosimilar Market – Introduction

    4.1    Overview
    4.2    WHO and FDA Terminology on Biosimilars
    4.3    Biosimilars and Generics
    4.4    Biosimilars and Branded Biological Products
5   Why are Biosimilars So Lucrative?
    5.1    Patent Expiry of Blockbuster Biological Drugs
    5.2    Significant Price Differential between Biosimilars and Innovator Drugs
    5.3    Savings for the Government and Third Party Payers
    5.4    Rising Prevalence of Lifestyle Diseases
    5.5    Incentives for Prescribers, Pharmacists and Patients
    5.6    Emergence of New Players in Europe and Emerging Markets
    5.7    Increasing Product Differentiation as Manufacturers Tie-Up with Drug Delivery Device Companies
6   Biosimilar Research, Development and Manufacturing
    6.1    Research and Development: Biosimilars vs. Innovator Drugs
    6.2    Manufacturing: Biosimilars vs. Innovator Drugs
7   Biosimilar Market
    7.1    Market Overview
    7.2    Historical Performance
    7.3    Impact of COVID-19
    7.4    Market Breakup by Segment
    7.5    Market Breakup by Manufacturing Type
    7.6    Market Breakup by Indication
    7.7    Market Breakup by Region
    7.8    Market Forecast
    7.9    Biosimilar Patent Landscape
        7.9.1    Patent Landscape in the US
        7.9.2    Patent Landscape in Europe
        7.9.3    Patent Landscape in Japan
    7.10    SWOT Analysis
        7.10.1    Overview
        7.10.2    Strengths
        7.10.3    Weaknesses
        7.10.4    Opportunities
        7.10.5    Threats
    7.11    Value Chain Analysis
        7.11.1   Characterizing the Existing Innovator Drug
        7.11.2   Research and Development
      Characterization of Biosimilars
      Developing a Unique Cell Line
        7.11.3   Product Development
      Intermediary Clinical Testing (PK/PD)
      Confirmatory Clinical Phase-III
        7.11.4   Final Product Formulation
        7.11.5   Marketing and Distribution
   7.12    Porter’s Five Forces Analysis
        7.12.1    Overview
        7.12.2    Bargaining Power of Buyers
        7.12.3    Bargaining Power of Suppliers
        7.12.4    Degree of Competition
        7.12.5    Threat of New Entrants
        7.12.6    Threat of Substitutes
    7.13    Price Analysis
        7.13.1    Key Price Indicators
        7.13.2    Price Trends
        7.13.3    Margin Analysis
8   Market Breakup by Molecule
    8.1    Infliximab
    8.2    Insulin Glargine
    8.3    Epoetin Alfa
    8.4    Etanercept
    8.5    Filgrastim
    8.6    Somatropin
    8.7    Rituximab
    8.8    Follitropin Alfa
    8.9    Adalimumab
    8.10    Pegfilgrastim
    8.11    Trastuzumab
    8.12    Bevacizumab
    8.13    Others
9   Market Breakup by Manufacturing Type
    9.1    In-house Manufacturing
        9.1.1    Market Trends
        9.1.2    Market Forecast
    9.2    Contract Manufacturing
        9.2.1    Market Trends
        9.2.2    Market Forecast
10  Market Breakup by Indication
    10.1    Auto-Immune Diseases
        10.1.1    Market Trends
        10.1.2    Market Forecast
    10.2    Blood Disorder
        10.2.1    Market Trends
        10.2.2    Market Forecast
    10.3    Diabetes
        10.3.1    Market Trends
        10.3.2    Market Forecast
    10.4    Oncology
        10.4.1    Market Trends
        10.4.2    Market Forecast
    10.5    Growth Deficiency
        10.5.1    Market Trends
        10.5.2    Market Forecast
    10.6    Female Infertility
        10.6.1    Market Trends
        10.6.2    Market Forecast
    10.7    Others
        10.7.1    Market Trends
        10.7.2    Market Forecast
11  Market Breakup by Region
    11.1    Europe
        11.1.1    Market Performance
        11.1.2    Key Players and Biosimilars
        11.1.3    Market Breakup by Country
        11.1.4    Market Forecast
        11.1.5    Italy
       Market Performance
       Key Players and Biosimilars
       Market Forecast
        11.1.6    Germany
       Market Performance
       Key Players and Biosimilars
       Market Forecast
        11.1.7    France
       Market Performance
       Key Players and Biosimilars
       Market Forecast
        11.1.8    United Kingdom
       Market Performance
       Key Players and Biosimilars
       Market Forecast
        11.1.9    Spain
       Market Performance
       Key Players and Biosimilars
       Market Forecast
        11.1.10    Rest of Europe
     Market Performance
     Market Forecast
    11.2    United States
        11.2.1    Current Market Trends
        11.2.2    Key Players and Biosimilars
        11.2.3    Market Forecast
    11.3    Japan
        11.3.1    Market Performance
        11.3.2    Key Players and Biosimilars
        11.3.3    Market Forecast
    11.4    India
        11.4.1    Current Market Trends
        11.4.2    Key Players and Biosimilars
        11.4.3    Market Forecast
    11.5    South Korea
        11.5.1    Current Market Trends
        11.5.2    Key Players and Biosimilars
        11.5.3    Market Forecast
    11.6    Rest of the World
        11.6.1    Current Market Trends
        11.6.2    Market Forecast
12  Requirements for Setting Up a Biosimilar Manufacturing Plant
    12.1    Manufacturing Process
    12.2    Raw Material Requirements
    12.3    Raw Material Pictures
    12.4    Land and Construction Requirements
    12.5    Machinery and Infrastructure Requirements
    12.6    Machinery Pictures
    12.7    Plant Layout
    12.8    Packaging Requirements
    12.9    Utility Requirements
    12.10    Manpower Requirements
13  Competitive Landscape
    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players
        13.3.1    Sandoz International GmbH
        13.3.2    Pfizer Inc.
        13.3.3    Teva Pharmaceutical Industries Limited 
        13.3.4    Celltrion Inc. 
        13.3.5    Biocon Limited
        13.3.6    Samsung Biologics 
        13.3.7    Amgen, Inc.
        13.3.8    Dr. Reddy’s Laboratories Limited
        13.3.9    Stada Arzneimittel Ag

About Us                                                                      

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St
Brooklyn, NY 11249, USA
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

Champagne Market

Leave a Reply

Your email address will not be published. Required fields are marked *